Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice

Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research. Developmental brain research 2003-03, Vol.141 (1), p.25-32
Hauptverfasser: Mesples, Bettina, Plaisant, Frank, Gressens, Pierre
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 32
container_issue 1
container_start_page 25
container_title Brain research. Developmental brain research
container_volume 141
creator Mesples, Bettina
Plaisant, Frank
Gressens, Pierre
description Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.
doi_str_mv 10.1016/S0165-3806(02)00636-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18729638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165380602006363</els_id><sourcerecordid>18729638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</originalsourceid><addsrcrecordid>eNqFkE9PwyAYhzlo3Jx-BA0no4cqUErpyZhlTpMlHtQzAfo2QdsyoTXz24vbokcvvAl5fu-fB6EzSq4poeLmOT1FlksiLgm7IkTkIssP0PT3e4KOY3wjhNBc0iM0oUxwzngxRctF04AdIvYNdv0AoYXx3fUZJdj3uAff60G3GDbWDX7wG2exCdr1uIXofB9TCHfOwgk6bHQb4XRfZ-j1fvEyf8hWT8vH-d0qs5zzIStqU0hpKOOsFJQXQKtcVkITaRgpS24aQ0peWSMI03UDstLUCsuFTQzXRT5DF7u-6-A_RoiD6ly00LY67TpGRWXJKpHLBBY70AYfY4BGrYPrdPhSlKgfa2prTf3oUYSprTWVp9z5fsBoOqj_UntlCbjdAZDO_HQQVLQOegu1C8mkqr37Z8Q3pqB9Gg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18729638</pqid></control><display><type>article</type><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</creator><creatorcontrib>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</creatorcontrib><description>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</description><identifier>ISSN: 0165-3806</identifier><identifier>DOI: 10.1016/S0165-3806(02)00636-3</identifier><identifier>PMID: 12644245</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Animals, Newborn ; Cell Death - drug effects ; Cell Death - genetics ; Cerebral Cortex - drug effects ; Cerebral Cortex - pathology ; Cerebral Cortex - physiopathology ; Cerebral palsy ; Cerebral Palsy - drug therapy ; Cerebral Palsy - immunology ; Cerebral Palsy - metabolism ; Drug Interactions - physiology ; Encephalitis - drug therapy ; Encephalitis - immunology ; Encephalitis - metabolism ; Excitotoxicity ; Female ; Ibotenic Acid - antagonists &amp; inhibitors ; Interleukin-1 - pharmacology ; Interleukin-1-beta ; Interleukin-10 - deficiency ; Interleukin-10 - genetics ; Interleukin-10 - pharmacology ; Interleukin-9 - pharmacology ; Interleukin-g ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microglia ; Microglia - drug effects ; Microglia - immunology ; Microglia - metabolism ; N-Methyl- d-aspartate ; Nerve Degeneration - drug therapy ; Nerve Degeneration - immunology ; Nerve Degeneration - metabolism ; Nerve Fibers, Myelinated - drug effects ; Nerve Fibers, Myelinated - immunology ; Nerve Fibers, Myelinated - metabolism ; Neurotoxins - antagonists &amp; inhibitors ; Survival Rate</subject><ispartof>Brain research. Developmental brain research, 2003-03, Vol.141 (1), p.25-32</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>Copyright 2002 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</citedby><cites>FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12644245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mesples, Bettina</creatorcontrib><creatorcontrib>Plaisant, Frank</creatorcontrib><creatorcontrib>Gressens, Pierre</creatorcontrib><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><title>Brain research. Developmental brain research</title><addtitle>Brain Res Dev Brain Res</addtitle><description>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</description><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Cell Death - drug effects</subject><subject>Cell Death - genetics</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - pathology</subject><subject>Cerebral Cortex - physiopathology</subject><subject>Cerebral palsy</subject><subject>Cerebral Palsy - drug therapy</subject><subject>Cerebral Palsy - immunology</subject><subject>Cerebral Palsy - metabolism</subject><subject>Drug Interactions - physiology</subject><subject>Encephalitis - drug therapy</subject><subject>Encephalitis - immunology</subject><subject>Encephalitis - metabolism</subject><subject>Excitotoxicity</subject><subject>Female</subject><subject>Ibotenic Acid - antagonists &amp; inhibitors</subject><subject>Interleukin-1 - pharmacology</subject><subject>Interleukin-1-beta</subject><subject>Interleukin-10 - deficiency</subject><subject>Interleukin-10 - genetics</subject><subject>Interleukin-10 - pharmacology</subject><subject>Interleukin-9 - pharmacology</subject><subject>Interleukin-g</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Microglia</subject><subject>Microglia - drug effects</subject><subject>Microglia - immunology</subject><subject>Microglia - metabolism</subject><subject>N-Methyl- d-aspartate</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - immunology</subject><subject>Nerve Degeneration - metabolism</subject><subject>Nerve Fibers, Myelinated - drug effects</subject><subject>Nerve Fibers, Myelinated - immunology</subject><subject>Nerve Fibers, Myelinated - metabolism</subject><subject>Neurotoxins - antagonists &amp; inhibitors</subject><subject>Survival Rate</subject><issn>0165-3806</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwyAYhzlo3Jx-BA0no4cqUErpyZhlTpMlHtQzAfo2QdsyoTXz24vbokcvvAl5fu-fB6EzSq4poeLmOT1FlksiLgm7IkTkIssP0PT3e4KOY3wjhNBc0iM0oUxwzngxRctF04AdIvYNdv0AoYXx3fUZJdj3uAff60G3GDbWDX7wG2exCdr1uIXofB9TCHfOwgk6bHQb4XRfZ-j1fvEyf8hWT8vH-d0qs5zzIStqU0hpKOOsFJQXQKtcVkITaRgpS24aQ0peWSMI03UDstLUCsuFTQzXRT5DF7u-6-A_RoiD6ly00LY67TpGRWXJKpHLBBY70AYfY4BGrYPrdPhSlKgfa2prTf3oUYSprTWVp9z5fsBoOqj_UntlCbjdAZDO_HQQVLQOegu1C8mkqr37Z8Q3pqB9Gg</recordid><startdate>20030314</startdate><enddate>20030314</enddate><creator>Mesples, Bettina</creator><creator>Plaisant, Frank</creator><creator>Gressens, Pierre</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20030314</creationdate><title>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</title><author>Mesples, Bettina ; Plaisant, Frank ; Gressens, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-5db588b124276145e193896a08b20774bfb0749cb602adfe89a1c6c46c6a04a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Cell Death - drug effects</topic><topic>Cell Death - genetics</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - pathology</topic><topic>Cerebral Cortex - physiopathology</topic><topic>Cerebral palsy</topic><topic>Cerebral Palsy - drug therapy</topic><topic>Cerebral Palsy - immunology</topic><topic>Cerebral Palsy - metabolism</topic><topic>Drug Interactions - physiology</topic><topic>Encephalitis - drug therapy</topic><topic>Encephalitis - immunology</topic><topic>Encephalitis - metabolism</topic><topic>Excitotoxicity</topic><topic>Female</topic><topic>Ibotenic Acid - antagonists &amp; inhibitors</topic><topic>Interleukin-1 - pharmacology</topic><topic>Interleukin-1-beta</topic><topic>Interleukin-10 - deficiency</topic><topic>Interleukin-10 - genetics</topic><topic>Interleukin-10 - pharmacology</topic><topic>Interleukin-9 - pharmacology</topic><topic>Interleukin-g</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Microglia</topic><topic>Microglia - drug effects</topic><topic>Microglia - immunology</topic><topic>Microglia - metabolism</topic><topic>N-Methyl- d-aspartate</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - immunology</topic><topic>Nerve Degeneration - metabolism</topic><topic>Nerve Fibers, Myelinated - drug effects</topic><topic>Nerve Fibers, Myelinated - immunology</topic><topic>Nerve Fibers, Myelinated - metabolism</topic><topic>Neurotoxins - antagonists &amp; inhibitors</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mesples, Bettina</creatorcontrib><creatorcontrib>Plaisant, Frank</creatorcontrib><creatorcontrib>Gressens, Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research. Developmental brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mesples, Bettina</au><au>Plaisant, Frank</au><au>Gressens, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice</atitle><jtitle>Brain research. Developmental brain research</jtitle><addtitle>Brain Res Dev Brain Res</addtitle><date>2003-03-14</date><risdate>2003</risdate><volume>141</volume><issue>1</issue><spage>25</spage><epage>32</epage><pages>25-32</pages><issn>0165-3806</issn><abstract>Interleukin-10 markedly reduces production of proinflammatory cytokines by activated microglia or macrophages and downregulates the expression of activating molecules on these cells. In studies performed in adults or in cell cultures, interleukin-10 protected against hypoxic–ischemic neuronal death and against lipopolysaccharide-mediated oligodendrocyte cell death. Furthermore, it was recently shown that interleukin-10 counteracts metabolic and microcirculatory effects of hypoxia–ischemia in the perinatal pig brain. Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions. The present study evaluated the influence of interleukin-10 on ibotenate-induced brain lesions in newborn mice under basal conditions or after exposure to cytokines. Intraperitoneal injection of interleukin-10 for 3 days following ibotenate significantly reduced the size of excitotoxic brain lesions. Intraperitoneal injection of neutralizing anti-interleukin-10 antibody for 3 days following ibotenate had no detectable effect and no difference in ibotenate-induced brain lesion size was found between wild type pups and pups deleted for the interleukin-10 gene, suggesting that endogenous interleukin-10 in newborn mice may have limited effects. Co-administration of intracerebral ibotenate and interleukin-10 had no detectable effect, arguing against a direct neuroprotective effect of interleukin-10 on neurons. While pretreatment with intraperitoneal interleukin-10 alone had no detectable effect on excitotoxic brain lesions, interleukin-10 given with interleukin-1-beta pretreatment blunted the toxic effects of interleukin-1-beta. On the other hand, combined pretreatment with IL-9 and anti-IL-10 antibody largely reversed the exacerbating effect of IL-9 on excitotoxic brain lesions. Altogether, these data suggest that, in newborn mice, exogenous interleukin-10 can be neuroprotective when acting in an inflammatory context.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>12644245</pmid><doi>10.1016/S0165-3806(02)00636-3</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-3806
ispartof Brain research. Developmental brain research, 2003-03, Vol.141 (1), p.25-32
issn 0165-3806
language eng
recordid cdi_proquest_miscellaneous_18729638
source MEDLINE; Alma/SFX Local Collection
subjects Animals
Animals, Newborn
Cell Death - drug effects
Cell Death - genetics
Cerebral Cortex - drug effects
Cerebral Cortex - pathology
Cerebral Cortex - physiopathology
Cerebral palsy
Cerebral Palsy - drug therapy
Cerebral Palsy - immunology
Cerebral Palsy - metabolism
Drug Interactions - physiology
Encephalitis - drug therapy
Encephalitis - immunology
Encephalitis - metabolism
Excitotoxicity
Female
Ibotenic Acid - antagonists & inhibitors
Interleukin-1 - pharmacology
Interleukin-1-beta
Interleukin-10 - deficiency
Interleukin-10 - genetics
Interleukin-10 - pharmacology
Interleukin-9 - pharmacology
Interleukin-g
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Microglia
Microglia - drug effects
Microglia - immunology
Microglia - metabolism
N-Methyl- d-aspartate
Nerve Degeneration - drug therapy
Nerve Degeneration - immunology
Nerve Degeneration - metabolism
Nerve Fibers, Myelinated - drug effects
Nerve Fibers, Myelinated - immunology
Nerve Fibers, Myelinated - metabolism
Neurotoxins - antagonists & inhibitors
Survival Rate
title Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20interleukin-10%20on%20neonatal%20excitotoxic%20brain%20lesions%20in%20mice&rft.jtitle=Brain%20research.%20Developmental%20brain%20research&rft.au=Mesples,%20Bettina&rft.date=2003-03-14&rft.volume=141&rft.issue=1&rft.spage=25&rft.epage=32&rft.pages=25-32&rft.issn=0165-3806&rft_id=info:doi/10.1016/S0165-3806(02)00636-3&rft_dat=%3Cproquest_cross%3E18729638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18729638&rft_id=info:pmid/12644245&rft_els_id=S0165380602006363&rfr_iscdi=true